Suppr超能文献

HuR在遗传性乳腺癌中的预后作用。

Prognostic role of HuR in hereditary breast cancer.

作者信息

Heinonen Mira, Fagerholm Rainer, Aaltonen Kirsimari, Kilpivaara Outi, Aittomäki Kristiina, Blomqvist Carl, Heikkilä Päivi, Haglund Caj, Nevanlinna Heli, Ristimäki Ari

机构信息

Department of Pathology/HUSLAB and Haartman Institute, Helsinki University Central Hospital, Finland.

出版信息

Clin Cancer Res. 2007 Dec 1;13(23):6959-63. doi: 10.1158/1078-0432.CCR-07-1432.

Abstract

PURPOSE

HuR is an mRNA-binding protein that enhances the stability of certain transcripts and can regulate their translation. Elevated cytoplasmic expression of HuR protein has been linked to carcinogenesis and is associated with reduced survival in breast, ovarian, and gastric adenocarcinomas.

EXPERIMENTAL DESIGN

Here, we have explored the relevance of HuR in familial breast cancer. Tumor samples were collected from patients with identified BRCA1 (n = 51) or BRCA2 (n = 47) mutations or familial non-BRCA1/2 cases (n = 525), and analyzed by immunohistochemistry.

RESULTS

Among familial non-BRCA1/2 breast cancer patients, cytoplasmic HuR protein expression was present in 39.4% of the cases and was associated with estrogen receptor negativity, progesterone receptor negativity, p53 positivity, high tumor grade, and ductal type of the tumor. In multivariate analysis, cytoplasmic HuR expression was an independent marker of reduced survival in the non-BRCA1/2 group along with tumor size >2 cm, lymph node metastasis, and high histologic grade. In patients with BRCA1 or BRCA2 mutations, cytoplasmic HuR expression was more frequent (62.7% for BRCA1 and 61.7% for BRCA2) than in the non-BRCA1/2 group, but in BRCA-mutated subgroups cytoplasmic HuR expression did not associate with survival.

CONCLUSIONS

Our results show that HuR is an important prognostic factor in familial breast cancer patients and may contribute to carcinogenesis in this disease.

摘要

目的

HuR是一种mRNA结合蛋白,可增强某些转录本的稳定性并能调节其翻译。HuR蛋白在细胞质中表达升高与致癌作用有关,且与乳腺癌、卵巢癌和胃腺癌患者生存率降低相关。

实验设计

在此,我们探讨了HuR在家族性乳腺癌中的相关性。从已鉴定出携带BRCA1(n = 51)或BRCA2(n = 47)突变的患者或家族性非BRCA1/2病例(n = 525)中收集肿瘤样本,并通过免疫组织化学进行分析。

结果

在家族性非BRCA1/2乳腺癌患者中,39.4%的病例存在细胞质HuR蛋白表达,且与雌激素受体阴性、孕激素受体阴性、p53阳性、高肿瘤分级以及肿瘤的导管类型相关。在多变量分析中,除肿瘤大小>2 cm、淋巴结转移和高组织学分级外,细胞质HuR表达是BRCA1/2基因野生型组患者生存率降低的独立标志物。在携带BRCA1或BRCA2突变的患者中,细胞质HuR表达比非BRCA1/2组更常见(BRCA1为62.7%,BRCA2为61.7%),但在BRCA突变亚组中,细胞质HuR表达与生存率无关。

结论

我们的结果表明,HuR是家族性乳腺癌患者的一个重要预后因素,可能在该疾病的致癌过程中起作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验